09:28:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 Ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2021-11-18 07:04:14
Oslo, Norway, 18 November 2021

Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company
developing targeted radiopharmaceuticals to extend and improve the lives of
patients with haematological cancers, will host an R&D Day on Tuesday, 30
November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting will be
held in person in Oslo and will also be available via a live webcast.

The meeting, intended for investors and analysts, will provide an overview of
the company's vision, progress to date, development pipeline and corporate
strategy.

Presentations will be delivered by members of Nordic Nanovector's executive
team, including new CEO, Erik Skullerud, and by Dr Leo I. Gordon, MD, FACP, a
global key opinion leader in haematology. Dr Gordon is Abby and John Friend
Professor of Cancer Research at the Northwestern University Feinberg School of
Medicine, and his research focus is to improve the outcome of patients with
lymphoma.

Agenda

14:00 - Welcome - Jan Egberts, Chairman

14:10 - Strategic reflections - Erik Skullerud, CEO

14:30 - Relapsed follicular lymphoma: evolving treatment algorithm and unmet
medical need - Leo Gordon, MD, Northwestern University

14:55 - Navigating the NHL landscape with Betalutin - Pierre Dodion, CMO

15:20 - Integrating targeted radioimmunotherapy in NHL care pathways - Marco
Renoldi, COO

15:35 - Break

15:45 - The CMC journey to BLA and launch readiness - Lars Nieba, CTO

16:00 - Nordic Nanovector pipeline: promising value-enhancing opportunities

· Alpha37: a CD37 targeted therapy for relapsed refractory CLL - Jostein
Dahle, CSO
· Beyond anti-CD37 radioimmunotherapy - Maureen Deehan, Head of Corporate
Development and Strategy

16:40 - Concluding Remarks - Erik Skullerud, CEO

Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Vika Auditorium

Please register to attend, please e-mail ir@nordicnanovector.com by 29 November
2021.

The webcast can be accessed
from www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?u
r
l=http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistr
a
va.com%7Ca91a12b7fd1942b911c508d9639fcaf4%7C5c24475f929349d0b4e1ba6d190e92f9%7C0
%
7C0%7C637650361008651083%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2l
u
MzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=hcy6kYrhFeRtQTxJ%2BodFi%2Fw%2BMH
p
8W%2F4umTDtDdJYsAg%3D&reserved=0) in the section: Investors & Media and a
recording will also be available on this page after the event.

The presentations will be available
at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7Ca91a12b7fd1942b911c508d9639fcaf4%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637650361008661079%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=YpIUKimx78JX14KG4Tcg6D3vx2RnTkqhO2
n
06S0%2B8ag%3D&reserved=0) in the section: Investors & Media/Reports and
Presentation/Presentations/2021 from 7:00am CET the same day.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 207 638 9571
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found
at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7Cb7a23ba8eace4c1e863308d97799ed1f%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637672326009184815%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=NOyVW%2B%2F3LdP8et7SyKO6Bze%2FFG2Z
%
2F4IBg8BfYb%2B87dU%3D&reserved=0).

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.